SG11202001162TA - Agents modulating beta-catenin functions and methods thereof - Google Patents

Agents modulating beta-catenin functions and methods thereof

Info

Publication number
SG11202001162TA
SG11202001162TA SG11202001162TA SG11202001162TA SG11202001162TA SG 11202001162T A SG11202001162T A SG 11202001162TA SG 11202001162T A SG11202001162T A SG 11202001162TA SG 11202001162T A SG11202001162T A SG 11202001162TA SG 11202001162T A SG11202001162T A SG 11202001162TA
Authority
SG
Singapore
Prior art keywords
methods
agents modulating
modulating beta
catenin functions
catenin
Prior art date
Application number
SG11202001162TA
Inventor
Gerard Hilinski
So Youn Shim
Matthew Patton
John Mcgee
Paula Ortet
Gregory Verdine
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of SG11202001162TA publication Critical patent/SG11202001162TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202001162TA 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof SG11202001162TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555519P 2017-09-07 2017-09-07
PCT/US2018/050102 WO2019051327A2 (en) 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof

Publications (1)

Publication Number Publication Date
SG11202001162TA true SG11202001162TA (en) 2020-03-30

Family

ID=65635271

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001162TA SG11202001162TA (en) 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof

Country Status (14)

Country Link
US (2) US11198713B2 (en)
EP (1) EP3678683A4 (en)
JP (1) JP2020533413A (en)
KR (1) KR20200064075A (en)
CN (1) CN111372942A (en)
AU (1) AU2018329956A1 (en)
BR (1) BR112020004555A2 (en)
CA (1) CA3074838A1 (en)
EA (1) EA202090513A1 (en)
IL (1) IL273015A (en)
MA (1) MA50101A (en)
MX (1) MX2020002435A (en)
SG (1) SG11202001162TA (en)
WO (1) WO2019051327A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074838A1 (en) 2017-09-07 2019-03-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
EP3883588A4 (en) 2018-11-21 2022-10-19 Endomet Biosciences, Inc. Compositions and methods for treating endometriosis
WO2021041895A1 (en) * 2019-08-30 2021-03-04 Ohio State Innovation Foundation Stapled beta-catenin ligands
EP4185599A2 (en) * 2020-07-22 2023-05-31 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
BR112023025528A2 (en) * 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc STAPLED PEPTIDES AND THESE METHODS

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
ES2367475T3 (en) 1999-10-15 2011-11-03 Avatar Medical, L.L.C. STABILIZED PROTEINS.
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
WO2004084809A2 (en) 2003-03-20 2004-10-07 Neuren Pharmaceuticals Ltd. Neuroprotective macrocylic compounds and methods for their use
EP1615613B1 (en) 2003-04-18 2009-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
CN107090025A (en) 2003-11-05 2017-08-25 达纳-法伯癌症研究所股份有限公司 Stable alpha helical peptides and application thereof
US20100029552A1 (en) 2004-08-20 2010-02-04 Phylogica Limited Peptide inhibitors of c-jun dimerization and uses thereof
EP1781324A2 (en) 2004-08-20 2007-05-09 Novo Nordisk A/S Pharmaceutically active insulin receptor-modulating molecules
KR20070094802A (en) 2004-12-20 2007-09-21 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. Myd88 homodimerization inhibitors
GB0511771D0 (en) 2005-06-09 2005-07-20 Novartis Ag Organic compounds
JP2010510236A (en) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． Stabilized MAML peptides and methods of use thereof
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CA2685568A1 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of treating diabetes using bad bh3 domain peptide
US20100273722A1 (en) 2007-08-06 2010-10-28 Yale University Modified miniature proteins
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5496897B2 (en) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド B7 family member zB7H6 and related compositions and methods
JP5788178B2 (en) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Compositions and methods for the treatment of viral infections
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
EP2342222B1 (en) 2008-09-22 2018-03-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2738983C (en) 2008-10-10 2018-05-15 Dana Farber Cancer Institute Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
CA2746256C (en) 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
CA2746265A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
CN102460175B (en) 2009-04-22 2014-09-10 沃尔特及伊莱萨霍尔医学研究院 Structure of the C-terminal region of the insulin receptor a-chain and of the insulin-like growth factor receptor a-chain
US9175038B2 (en) 2009-05-15 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
EP3698810A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2012006598A2 (en) 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
DE102009032902A1 (en) 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induction of α-helix conformations in proteins and peptides
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011094708A2 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
WO2011146974A1 (en) 2010-05-25 2011-12-01 Monash University Methods for the synthesis of alkyne-containing dicarba bridges in peptides
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
WO2012082891A1 (en) 2010-12-14 2012-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptide inhibitors of wnt pathway
JP6086067B2 (en) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon analog showing GIP receptor activity
AU2012242502B2 (en) 2011-04-15 2016-07-28 Dana-Farber Cancer Institute, Inc. Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
US9303024B2 (en) 2011-10-11 2016-04-05 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic BAX
CA2862391C (en) 2011-12-29 2023-10-10 Loren D. Walensky Stabilized antiviral fusion helices
WO2013142281A1 (en) 2012-03-20 2013-09-26 Dana Farber Cancer Institute, Inc. Inhibition of mcl-1 and/or bfl-1/a1
EP2901154B1 (en) 2012-09-25 2018-11-21 The Walter and Eliza Hall Institute of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
PT2920197T (en) 2012-09-26 2021-06-11 Harvard College Proline-locked stapled peptides and uses thereof
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
WO2014159969A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
CA2906740A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
EP3572422A1 (en) 2013-03-15 2019-11-27 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
CA2906572A1 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
KR20160019547A (en) 2013-06-14 2016-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stabilized polypeptide insulin receptor modulators
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
CN106573032B (en) 2014-05-21 2022-03-18 哈佛大学的校长及成员们 RAS inhibitory peptides and uses thereof
JP2018511594A (en) 2015-03-18 2018-04-26 マサチューセッツ インスティテュート オブ テクノロジー Selective MCL-1-binding peptide
BR112017028413A2 (en) 2015-07-02 2018-08-28 Dana Farber Cancer Inst Inc stabilized antimicrobial peptides
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
JP7049989B2 (en) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Peptide that binds to BFL-1
CN117304295A (en) 2015-10-05 2023-12-29 北京佳诚生物医药科技开发有限公司 Stabilized BCL9 peptides for the treatment of aberrant Wnt signaling
US20190048038A1 (en) * 2016-02-23 2019-02-14 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
CA3074838A1 (en) 2017-09-07 2019-03-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
CA3110082A1 (en) * 2018-08-20 2020-02-27 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
JP2023505691A (en) 2019-12-11 2023-02-10 フォグ ファーマシューティカルズ， インコーポレイテッド Techniques useful for evaluating permeability
WO2021188659A1 (en) 2020-03-17 2021-09-23 Fog Pharmaceuticals, Inc. Helical stapled peptides and uses thereof
WO2022020651A1 (en) 2020-07-22 2022-01-27 Fog Pharmaceuticals, Inc. Amino acids
EP4185599A2 (en) 2020-07-22 2023-05-31 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
BR112023025528A2 (en) 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc STAPLED PEPTIDES AND THESE METHODS

Also Published As

Publication number Publication date
CN111372942A (en) 2020-07-03
KR20200064075A (en) 2020-06-05
EP3678683A4 (en) 2021-07-14
US11834482B2 (en) 2023-12-05
US20220213154A1 (en) 2022-07-07
JP2020533413A (en) 2020-11-19
WO2019051327A3 (en) 2019-04-18
MX2020002435A (en) 2020-09-22
CA3074838A1 (en) 2019-03-14
EP3678683A2 (en) 2020-07-15
AU2018329956A1 (en) 2020-08-20
US20200247858A1 (en) 2020-08-06
US11198713B2 (en) 2021-12-14
MA50101A (en) 2020-07-15
IL273015A (en) 2020-04-30
WO2019051327A2 (en) 2019-03-14
BR112020004555A2 (en) 2020-09-24
EA202090513A1 (en) 2020-08-24

Similar Documents

Publication Publication Date Title
IL290842A (en) Anti-cd73 antibodies and uses thereof
IL268206A (en) Bcma-targeting antibody and use thereof
IL280648A (en) Anti-galectin-9 antibodies and uses thereof
IL271025A (en) Multibiotic agents and methods of using the same
IL268734A (en) Anti-lag-3 antibodies and uses thereof
IL268700A (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and uses thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
IL273015A (en) Agents modulating beta-catenin functions and methods thereof
IL275577A (en) Antibodies and variants thereof against pd-l1
GB201714745D0 (en) New compounds and uses
IL272476A (en) Anti-apelin antibodies and uses thereof
SG11202004877UA (en) Sulfonamide compounds and use thereof
GB201714740D0 (en) New compounds and uses
IL273157A (en) Axl-specific antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
GB201714734D0 (en) New compounds and uses
GB201712032D0 (en) Antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
GB201714736D0 (en) New compounds and uses
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
ZA201905513B (en) Rorgamma modulators and uses thereof
ZA201905511B (en) Rorgamma modulators and uses thereof
IL269836B (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
GB201712110D0 (en) New compounds and uses